Correspondence 0001193125-24-151740 from T2 Biosystems, Inc. (TTOO) (CIK 0001492674)
T2 Biosystems, Inc. (TTOO) (CIK 0001492674)
Date: May 31, 2024 · CIK: 0001492674 · Accession: 0001193125-24-151740
AI Filing Summary & Sentiment
File numbers found in text: 333-279740
Letter
T2 Biosystems, Inc.
101 Hartwell Avenue
Lexington, Massachusetts 02421
May 31, 2024
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: T2 Biosystems, Inc.
Registration Statement on Form S-3
Filed May 28, 2024
File No. 333-279740
To whom it may concern:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, T2 Biosystems, Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-279740) be accelerated by the Securities and Exchange Commission to 4:30 p.m. Washington D.C. time on June 4, 2024 or as soon as practicable thereafter.
The Company requests that we be notified of such effectiveness by a telephone call to N. Danny Shulman of Latham & Watkins LLP at (212) 906-4510 and that such effectiveness also be confirmed in writing.
Very truly yours,
T2 Biosystems, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP T2 Biosystems, Inc. 101 Hartwell Avenue Lexington, Massachusetts 02421 May 31, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: T2 Biosystems, Inc. Registration Statement on Form S-3 Filed May 28, 2024 File No. 333-279740 To whom it may concern: Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, T2 Biosystems, Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-279740) be accelerated by the Securities and Exchange Commission to 4:30 p.m. Washington D.C. time on June 4, 2024 or as soon as practicable thereafter. The Company requests that we be notified of such effectiveness by a telephone call to N. Danny Shulman of Latham & Watkins LLP at (212) 906-4510 and that such effectiveness also be confirmed in writing. Very truly yours, T2 Biosystems, Inc. By: /s/ John Sperzel John Sperzel President, Chief Executive Officer and Chairman of the Board cc: Evan Smith, Latham & Watkins LLP Steven Stokdyk, Latham & Watkins LLP